ArticleNPJ precision oncology2025

Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study.

Zhenlin Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.